MarketInOut Stock Screener Log In | Sign Up

Belite Bio Inc ADR

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Belite Bio Inc ADR stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization6,231.71 mln
Float39.55 mln
Earnings Date11/17/2026

1-Year Forecast

227.44
Exceptional upside

Relative Strength

90 / 100
Top performer

ROE

-18.50
Negative

ROA

-18.14
Deeply negative

Business Description

Belite Bio is a San Diego-based drug development company focused on creating treatments for serious eye conditions that currently have few or no effective options. Its most advanced drug, Tinlarebant, is taken by mouth and is currently in Phase 3 trials for patients with Stargardt disease and geographic atrophy, two conditions that cause progressive vision loss. The company is also working on a separate oral drug targeting liver disease, type 2 diabetes, and gout. Founded in 2016, Belite Bio operates as part of Lin Bioscience International Ltd.

Key Fundamentals

EPS-2.83
ROE-18.50
ROIC-44.01
ROA-18.14
EBITDA, mln-102
EV / EBITDA-54.87
EV / EBIT-54.62

Quote Details

Last 154.74
Change 4.46 (2.97%)
Open 148.79
Volume 234,874
Turnover 36,344,404
Average Volume 153,294

Financial Ratios

Leverage Ratio1.02
Current Ratio33.56
Price / Book7.56
Price / Tangible Book7.55

Financial Strength

1-Year Target Price227.44
Short Ratio7.77
Short % of Float6.03

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 5.03% 88 / 100   
1 Month -5.06% 39 / 100   
2 Months -2.33% 47 / 100   
6 Months -0.07% 56 / 100   
1 Year 57.9% 93 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog